F de Blay1, P Kuna2, L Prieto3, T Ginko4, D Seitzberg5, B Riis5, G W Canonica6. 1. Chest Disease Department, University Hospital of Strasbourg, Federation of Translational Medicine, EA 3072, 67091 Strasbourg University, France. Electronic address: Frederic.DEBLAY@chru-strasbourg.fr. 2. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, ul. Kopcińskiego 22, 90-153 Łódź, Poland. 3. Departamento de Medicina, Universidad de Valencia, Av. Blásco Ibáñez, 15, 46010 Valencia, Spain. 4. Private Practice, Vorgebirgsstraße 43, 53119 Bonn, Germany. 5. Global Clinical Development, ALK, Bøge Allé 6-8, 2970 Hørsholm, Denmark. 6. Allergy & Respiratory Dis. Clinic, DIMI, University of Genova, IRCCS AOU San Martino, Largo R. Benzi 10, 16132 Genova, Italy.
Abstract
INTRODUCTION: In a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20), the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) was investigated. METHOD: The trial included 604 subjects, ≥14 years, with mild-moderate HDM allergic asthma. Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was analysed post hoc in a subgroup with daily ICS use of 400-800 μg and ACQ score of 1-1.5, corresponding to partly controlled asthma (N = 108). RESULTS: The trial met its primary endpoint. In the subgroup, the difference between placebo and 6 SQ-HDM in change from baseline in daily ICS use was 327 μg (p < 0.0001), while it was 0.52 (p = 0.010) for AQLQ. The treatment effect on ICS reduction and AQLQ was increased for the subgroup versus the residual population (ICS reduction: p < 0.001); AQLQ: p = 0.044). CONCLUSION: In this subgroup, including only patients with partly controlled asthma, the benefit of 1 year of treatment with SQ HDM SLIT-tablet was significantly higher than for the less severe full population, both in terms of increased asthma control and improved quality of life.
RCT Entities:
INTRODUCTION: In a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20), the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) was investigated. METHOD: The trial included 604 subjects, ≥14 years, with mild-moderate HDM allergic asthma. Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was analysed post hoc in a subgroup with daily ICS use of 400-800 μg and ACQ score of 1-1.5, corresponding to partly controlled asthma (N = 108). RESULTS: The trial met its primary endpoint. In the subgroup, the difference between placebo and 6 SQ-HDM in change from baseline in daily ICS use was 327 μg (p < 0.0001), while it was 0.52 (p = 0.010) for AQLQ. The treatment effect on ICS reduction and AQLQ was increased for the subgroup versus the residual population (ICS reduction: p < 0.001); AQLQ: p = 0.044). CONCLUSION: In this subgroup, including only patients with partly controlled asthma, the benefit of 1 year of treatment with SQ HDM SLIT-tablet was significantly higher than for the less severe full population, both in terms of increased asthma control and improved quality of life.
Authors: Erick Forno; Joanne Sordillo; John Brehm; Wei Chen; Takis Benos; Qi Yan; Lydiana Avila; Manuel Soto-Quirós; Michelle M Cloutier; Angel Colón-Semidey; Maria Alvarez; Edna Acosta-Pérez; Scott T Weiss; Augusto A Litonjua; Glorisa Canino; Juan C Celedón Journal: J Allergy Clin Immunol Date: 2017-02-04 Impact factor: 10.793
Authors: Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh Journal: J Allergy Clin Immunol Date: 2020-12 Impact factor: 10.793
Authors: Giorgio Walter Canonica; Gianenrico Senna; Patrick D Mitchell; Paul M O'Byrne; Giovanni Passalacqua; Gilda Varricchi Journal: World Allergy Organ J Date: 2016-11-28 Impact factor: 4.084